Ben Venue Signs Consent Decree With FDA To Address Manufacturing Problems at Plant

Ohio-based drug manufacturer Ben Venue Laboratories Inc. (BVL) Jan. 22 said that it voluntarily entered into a consent decree with the Food and Drug Administration related to current good manufacturing practice requirements or cGMPs (United States v. Ben Venue Laboratories).

Under the terms of the consent decree, the drug company, which is part of German drug company Boehringer Ingelheim, is permitted to continue to manufacture and distribute “more than one hundred important drugs that are essential for patient care,” the company said in a statement. The company’s Ohio plant had been shut down voluntarily in 2011 due to ...